Cocrystal Pharma Inc COCP

Healthcare

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.

NDAQ:COCP - Post by User

Cocrystal Pharma Inc > covid-19 related news.

<< Previous

Bullboard Posts

Next >>

Comment by rustadson Mar 08, 2020 10:00pm

89 Views

Post# 30781658

RE:covid-19 related news.

This one is going to have a big move to $4 like the rest did lastweek. Perfect timing and once we have the cure this stock is going back to the glory days of $100. GLTA Monday

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Cannabis Report – May 3, 2024